{
  "emaEpar": [
    {
      "activeSubstance": "pixantrone dimaleate",
      "conditionIndication": "Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy.",
      "inn": "pixantrone dimaleate",
      "marketingAuthorisationDate": "2012-05-10 00:00:00",
      "marketingAuthorisationHolder": "Les Laboratoires Servier",
      "medicineName": "Pixuvri",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri"
    }
  ],
  "fdaDrugLabel": [],
  "id": "Pixantrone_Dimaleate",
  "nciThesaurus": {
    "casRegistry": "144675-97-8",
    "chebiId": "",
    "chemicalFormula": "C17H19N5O2.2C4H4O4",
    "definition": "The dimaleate salt of a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.",
    "fdaUniiCode": "P0R64C4CR9",
    "identifier": "C82398",
    "preferredName": "Pixantrone Dimaleate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C582"
    ],
    "synonyms": [
      "6,9-Bis((2-Aminoethyl)Amino)Benzo(g)Isoquinoline-5,10-Dione (2z)-But-2-Enedioate (1:2)",
      "BBR 2778",
      "Benz(g)Isoquinoline-5,10-Dione, 6,9-Bis((2-Aminoethyl)Amino)-, (2z)-2-Butenedioate (1:2)",
      "Benz(g)isoquinoline-5,10-dione, 6,9-bis((2-aminoethyl)amino)-, (2Z)-2-butenedioate (1:2)",
      "PIXANTRONE DIMALEATE",
      "Pixantrone Dimaleate",
      "Pixantrone Maleate"
    ]
  }
}